OccuLogix, Inc. Product Pipeline Analysis

Global Markets Direct, January 2009, Pages: 26

OccuLogix, Inc. Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Scope’s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

- Details of development stage by sector and equipment type.
- Pipeline products grouped by therapy area, development stage and trial phase.
- Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
- Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
- Product updates covering estimated approval dates and estimated launch dates.
- Descriptions of novel technologies relating to pipeline products of the company.
- Patents and patent applications covered for the product.
- News updates on key events relating to the product and its development.

Reasons to buy

- A single source to fulfill competitor information relating to products in development.
- Identify pipeline products that are potential competitor to your product lines.
- Understand a companys strategic position by accessing detailed independent intelligence on its product pipeline.
- Access clinical trial information to map trial results and plan targeted marketing activities.
- Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
- Identification of potential investment opportunities.
- Build up knowledge base for potential distribution and marketing partners.
- Helps avoid patent infringement.
- Timelines from concept to market lets you keep track of market potential build for a new product.
- Assess a companys future growth by determining its pipeline depth, for probable acquisition opportunities.

1
1 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Company Snapshot 6
2.1 Key Information 6
2.2 Company Overview 6
3 OccuLogix, Inc. Pipeline Products 7
3.1 OccuLogix, Inc. Product Pipeline Analysis 7
3.1.1 OccuLogix, Inc. Pipeline Products By Equipment Type 7
3.1.2 OccuLogix, Inc. Pipeline Products By Development Stage 7
3.1.3 OccuLogix, Inc. Pipeline Products By Therapy Area 8
3.1.4 OccuLogix, Inc. Pipeline Products By Clinical Trials 8
3.1.5 OccuLogix, Inc. Pipeline Products By News Summary 9
3.2 SOLX Gold Shunt 10
3.2.1 Product Status 10
3.2.2 Product Description 10
3.2.3 Product Milestone 10
3.2.4 Clinical Trials 11
3.3 SOLX 790 Laser 12
3.3.1 Product Status 12
3.3.2 Product Description 12
3.3.3 Product Milestone 13
3.3.4 Clinical Trials 14
3.4 RHEO system 15
3.4.1 Product Status 15
3.4.2 Product Description 15
3.4.3 Product Milestone 16
3.4.4 RHEO systemClinical Trials 1 16
3.4.5 RHEO systemClinical Trials 2 17
3.4.6 RHEO systemClinical Trials 3 18
3.5 Implantable IOP sensor 18
3.5.1 Product Status 18
3.5.2 Product Description 19
3.6 TearLab Osmolarity Test Card 19
3.6.1 Product Status 19
3.6.2 Product Description 19
4 Recent Developments 20
4.1 Product News 20
4.1.1 Dec 01, 2007: Occulogix To Seek US Approval For Glaucoma Laser 20
4.1.2 May 30, 2007: Solx Gold Shunt Promising For Managing IOP, Surgeons Say 20
4.1.3 Apr 30, 2007: Gold Drainage Device In Glaucoma Patients 20
4.1.4 Nov 11, 2006: SOLX Establishes International Certification Program 21
4.1.5 Jan 15, 2006: Gold Microshunt Implantation May Be An Option For Lowering IOP 21
4.1.6 Nov 17, 2005: All 12-Month Follow-up Visits Completed In OccuLogixs Pivotal Trial For Dry Age-Related Macular Degeneration 21
4.1.7 Aug 01, 2005: Micro-Shunt, Laser Duo A Novel Glaucoma Therapy 22
4.2 Clinical Trials 22
4.2.1 Apr 30, 2007: Gold Drainage Device In Glaucoma Patients 22
4.2.2 Nov 17, 2005: All 12-Month Follow-up Visits Completed In OccuLogixs Pivotal Trial For Dry Age-Related Macular Degeneration 22
4.2.3 Aug 01, 2005: Micro-Shunt, Laser Duo A Novel Glaucoma Therapy 22
5 Appendix 24
5.1 Methodology 24
5.1.1 Coverage 24
5.1.2 Secondary Research 25
5.1.3 Primary Research 25
5.1.4 Expert Panel Validation 26
5.2 Contact Us 26
5.3 About us26
5.4 Disclaimer 26

Executive Summary

1.2 List of Figures
Figure 1: OccuLogix, Inc. Pipeline Products By Development Stage 7
Figure 2: OccuLogix, Inc. Pipeline Products By News Summary 9
Figure 3: Global Markets Direct Methodology 24

The following companies are the major competitors of OccuLogix, Inc.:
Alcon, Inc.
Eyetech Pharmaceuticals, Inc.
Genentech, Inc.
QLT Inc.
Regeneron Pharmaceuticals, Inc.

Customers who bought this item also bought

• Therapeutic Apheresis - Global Strategic Business Report
• Global Glaucoma Drug Pipeline Capsule - 2012
• Competitor Analysis: Wet Age-Related Macular Degeneration (AMD)
• Clinical Trial Management Systems (CTMS) - Global Strategic Business Report
• Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US
• PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013
• Healthcare Contract Research Outsourcing Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018
• 2012 Good Clinical Practice: A Question & Answer Reference Guide
• Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma
• Global HIV Drug Pipeline Capsule - 2012